| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -27.0 | -18.0 |
| Net income | -25.8 | -18.0 |
| EPS (diluted, $ a share) | $-0.20 | $-0.21 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ZURA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Zura Bio Ltd: key numbers
- Share price
- $1.08Close, Nov 16
- Market cap
- $104M
- Shares outstanding
- 96.33MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Zura Bio Ltd
All →Zura Bio Clinical Trial Data
Zura Bio announced that its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa (HS) failed to meet its primary endpoint of percentage change from baseline in total abscess and inflammatory nodule count at Week 16. Key secondary endpoints were also not met, leading the company to discontinue development of the drug for the HS indication. Zura will continue its ongoing trials for tibulizumab in systemic sclerosis and polymyalgia rheumatica.
Zura Bio Financial Results
Zura Bio reported third quarter 2026 financial results, highlighting a cash position of $187.7 million which is expected to fund operations through 2028. The company remains on track for topline Phase 2 data readouts for tibulizumab in hidradenitis suppurativa (Q4 2026) and systemic sclerosis (H1 2027).
“Our team continues to execute efficiently on our development plan for tibulizumab, and we are excited as we enter this data-rich period for the company. We are on track to report topline results from our TibuSHIELD study in HS later this quarter, followed by topline results from our TibuSURE study in SSc in the first half of 2027.”
Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer
“We continue to believe deeply in tibulizumab’s potential to address complex immune biology and unmet needs across indications, including in PMR, where we will be starting the NEXUS-PMR study by end of year. With cash runway sufficient to deliver results from all three studies, Zura is in a great position to deliver on tibulizumab’s unique potential.”
Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer